Trial Profile
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs FCR 001 (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Talaris Therapeutics
- 28 Jun 2023 Results of immunocompetence and biomarkers of tolerance in chimeric and immunosuppression- free kidney allograft recipients, published in the Transplantation
- 03 May 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Nov 2022 According to a Talaris Therapeutics media release, data from the trial was presented at the 2022 American Society of Nephrology (ASN) Annual Meeting.